English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aims/Introduction  α‐Glucosidase inhibitors (α GI s) are widely used for the primary treatment of type 2 diabetes. We compared the clinical effects of three α GI s (miglitol, acarbose and voglibose) in patients with obese type 2 diabetes.    Materials and Methods  Japanese patients ( n  = 81) with obese type 2 diabetes (body mass index [ BMI ] ≥25 kg/m 2 ) were enrolled in this multicenter, open‐label study. The participants were randomized into the miglitol ( n  = 18), acarbose ( n  = 22), voglibose ( n  = 19) or control ( n  = 22) groups. Glycemic control (fasting blood glucose and glycated hemoglobin [HbA1c]), bodyweight,  BMI , serum insulin, serum lipids (low‐density lipoprotein and high‐density lipoprotein cholesterol, and triacylglycerols) and adipocytokines (leptin and adiponectin) were evaluated every 4 weeks for 12 weeks.    Results  In the miglitol group,  H b A 1c was improved significantly from the baseline at all points. The changes in  H b A 1c at 8 and 12 weeks from baseline were greater in the miglitol group than the control group. The voglibose group showed significant improvements in  H b A 1c at 12 weeks. Bodyweight and  BMI  were decreased significantly in the miglitol group. In addition, significant correlations were observed between the decrements in  H b A 1c and bodyweights over 12 weeks in the miglitol ( r  = 0.759,  P  < 0.001) and voglibose groups ( r  = 0.667,  P  = 0.002). Serum lipid and adipocytokine levels were not altered in any groups.    Conclusions  α GI s, especially miglitol, can effectively control blood glucose and bodyweight in obese type 2 diabetes. This study was registered with  UMIN  (no.  UMIN 6465).

Comparison of three α‐glucosidase inhibitors for glycemic control and bodyweight reduction in J apanese patients with obese type 2 diabetes